98%
921
2 minutes
20
Pseudohypoparathyroidism (PHP) is an uncommon endocrine condition marked by an impaired response to parathyroid hormone (PTH), which results in biochemical abnormalities. Clinical manifestations can vary significantly, occasionally resembling other endocrine disorders. Genetic testing plays a critical role in distinguishing PHP from other conditions, as it enables precise diagnosis even when classical features are not initially present. We report the case of a male infant initially diagnosed with congenital hypothyroidism (CH) through neonatal screening and treated with levothyroxine. While growing up, the patient developed syndromic features, including facial dysmorphisms, global developmental delay, behavioural issues, and early-onset obesity. Whole exome sequencing (WES), prompted by the complex phenotype, identified a maternally inherited variant. This led to the suspicion of PHP1A, which was subsequently confirmed at five years of age when laboratory reevaluation revealed hypocalcemia, hyperphosphatemia, and elevated PTH levels. PHP can mimic isolated CH in early presentations, often delaying recognition. This case underscores the pivotal role of genetic testing in diagnosing PHP. Early genetic evaluation and multidisciplinary care are essential for accurate diagnosis, tailored treatment, and long-term monitoring, ultimately improving patient outcomes.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11928234 | PMC |
http://dx.doi.org/10.7759/cureus.79321 | DOI Listing |
Urol J
September 2025
Department of Child and Adolescent Psychiatry, Faculty of Medicine, Recep Tayyip Erdogan University, Rize, TURKIYE.
Purpose: This study aimed to investigate the genetic heterogeneity of primary monosymptomatic nocturnal enuresis (PMNE) and assess potential genetic variants contributing to its etiology.
Materials And Methods: A total of 92 children aged 5-15 years with a positive family history of PMNE were evaluated. All patients underwent detailed urological and nephrological assessments to exclude organic causes.
Am J Kidney Dis
September 2025
Department of Pathology, Stanford University School of Medicine, Stanford, CA 94305. Electronic address:
Forensic Sci Int
August 2025
Department of Laboratory Medicine and Pathobiology, University of Toronto, Canada.
We report the forensic and clinicopathological spectrum of 14 postmortem cases involving the vertebral artery. In all cases, there was either pontocerebellar infarction (n = 8) or subarachnoid hemorrhage (n = 6). The underlying pathology of the vertebral artery was segmental mediolytic arteriopathy (n = 5), traumatic rupture of the arterial wall (n = 3), arterial dissection (n = 2), or atherosclerosis (n = 4).
View Article and Find Full Text PDFJ Environ Radioact
September 2025
Semey Medical University, Semey, 071407, Republic of Kazakhstan. Electronic address:
At Semipalatinsk nuclear test site (SNTS), nuclear weapons tests lasted from 1949 to 1989, with a total of 468 nuclear weapons explosions (including 117 air and ground tests) being conducted. The aim of our study is to evaluate trends in the field of conducted research on the assessment of the health status of the population of Kazakhstan exposed to radiation as a result of nuclear weapons testing at the STNS, as well as the contribution of various countries, institutions, journals and authors to these studies. Research methods included: formulating research questions; selecting databases to search for the information of interest; collecting information on publications; selecting a program to conduct bibliometric analysis; creating maps according to research questions; analyzing bibliometric data.
View Article and Find Full Text PDFUltrasound Obstet Gynecol
September 2025
Department of Clinical Genetics, Erasmus MC, University Medical Centre, Rotterdam, The Netherlands.
Objective: To evaluate the performance of non-invasive prenatal testing (NIPT) in vanishing-twin and multiple pregnancies.
Methods: This study was conducted as part of the TRIDENT-2 study, in which NIPT was offered as a first-tier screening test to women with a multiple pregnancy or vanishing-twin pregnancy between 1 June 2020 and 31 March 2023 in The Netherlands. Abnormal NIPT results were investigated by follow-up invasive prenatal testing and/or postnatal genetic testing.